文献速递主动脉疾病

腹主动脉瘤EVAR术后2型内漏再干预的多中心回顾性研究:早期与随访结果

Early and follow-up results of reinterventions for type 2 endoleak following endovascular repair of abdominal aortic aneurysm (EVAR): the multicenter REinterventions for Type 2 Endoleak (RETE) study.
PubMed 文献 · J Vasc Surg · 2026-10-20

REinterventions for Type 2 Endoleak(RETE)研究回顾性分析了20个高容量中心10年间403例因2型内漏(T2EL)首次再干预的患者。再干预指征以瘤囊增大为主(94.5%),技术成功率96%,围术期死亡率1%;5年总生存率80.5%,无破裂生存率79.2%,但T2EL复发率64.2%,无再干预生存率48.3%。腔内再干预组的无再干预率显著低于开放转换/半转换组(42.4% vs 86.8%,p<0.001)。

要点

  • T2EL再干预安全,技术成功率96%,围术期死亡率1%。
  • 5年T2EL复发率64.2%,超过40%患者需再次干预。
  • 再干预时瘤囊直径≥7 cm预测需进一步再干预,初次开放治疗耐久性更优。

核心结论

  • T2EL再干预安全,围术期死亡率和主要并发症率低,但5年复发率超过60%,超过40%患者需再次干预。
  • 腔内再干预的无再干预生存率显著低于开放转换/半转换组(42.4% vs 86.8%,p<0.001)。
  • 再干预时瘤囊直径≥7 cm预测进一步再干预,初次开放治疗可改善耐久性。

研究设计与样本

  • 多中心回顾性分析,纳入20个高容量学术中心10年间连续接受T2EL首次再干预的患者。
  • 排除需同期治疗其他类型内漏的患者,共纳入403例。
  • 主要结局包括技术成功、30天动脉瘤相关死亡和无再干预生存;随访分析采用Kaplan-Meier曲线和Cox回归。

主要发现

  • 患者90%为男性,平均年龄77岁;再干预指征中瘤囊增大占94.5%,破裂占4%。
  • 从EVAR到再干预的中位时间4.3年;内漏来源主要为腰动脉(55%)和肠系膜下动脉(35%)。
  • 腔内治疗占86%,开放转换/半转换占14%;技术成功96%,死亡率1%,主要并发症4%。
  • 5年总生存率80.5%,无破裂生存率79.2%;T2EL复发率64.2%,无再干预生存率48.3%。
  • 腔内组无再干预率显著低于开放转换/半转换组(42.4% vs 86.8%,SE 0.04 vs SE 0.05,p<0.001,log-rank 15.9);腔内治疗后转换/半转换占14%。

临床怎么用

  • T2EL再干预可安全施行,但需告知患者高复发率和再干预风险。
  • 对瘤囊直径接近7 cm的患者可建议早期干预。
  • 低风险患者可考虑初次开放转换/半转换以改善耐久性。

局限性

  • 回顾性研究设计。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type II endoleak (T2EL) is frequent after endovascular abdominal aortic aneurysm repair (EVAR) and may require reintervention in selected patients. However, the optimal treatment strategy for durable resolution remains uncertain. The aim of this study is to retrospectively analyze perioperative and long-term results of T2Els' reinterventions, both endovascular and open surgical, in a large patient cohort from twenty high-volume academic centers. METHODS: A retrospective analysis of consecutive patients undergoing first reintervention for T2ELs was conducted across 20 centers over a 10-year period. Patients requiring concomitant treatment for other endoleak types were excluded. A total of 403 patients were included. Primary outcomes included technical success, 30-day AAA-related mortality and reintervention-free survival during follow-up. Secondary outcomes were perioperative complications, early reintervention, overall survival, freedom from aneurysm-related death and rupture, freedom from recurrent endoleaks, freedom from open conversion or semi-conversion in patients previously treated endovascularly and sac behavior during follow-up. Kaplan-Meier curves and Cox regression analyses were performed to analyze follow-up results. RESULTS: Patients were predominantly male (90%) with a mean age of 77 years. Reintervention was indicated for sac enlargement in 94.5% of cases; 4% presented with rupture. Median time from EVAR to reintervention was 4.3 years. Lumbar arteries (55%) and the inferior mesenteric artery (35%) were the main sources. Endovascular treatment was performed in 86% and open conversion/semi-conversion in 14%. Technical success was 96%, with 1% mortality and 4% major complications. Overall survival was 80.5% and rupture-free survival 79.2% at 5 years. Recurrent T2EL occurred in 64.2%, and reintervention-free survival was 48.3%. Endovascular group showed significantly lower freedom from reintervention rates when compared to open conversion/semi conversion group (42.4% vs 86.8%, SE 0.04 vs SE 0.05, p<0.001, log-rank 15.9). Conversion/semi-conversion after endovascular treatment occurred in 14%. No differences were recorded comparing different fabric materials of the endograft in terms of freedom for reintervention and freedom from open surgery. A sac diameter ≥7 cm at the time of reintervention predicted further reinterventions, while primary open treatment improved durability. CONCLUSIONS: Reinterventions for T2ELs are safe, with satisfactory immediate technical success and low perioperative mortality. During follow-up, risks of rupture and AAA-related death remain low. However, the endoleak recurrence rate exceeds 60% at five years, necessitating reintervention in over 40% of patients. Early intervention for patients with a sac diameter approaching 7 cm can be suggested, while a primary open approach may be considered in low-risk patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Falso R, Speziali S, Perini P, et al. Early and follow-up results of reinterventions for type 2 endoleak following endovascular repair of abdominal aortic aneurysm (EVAR): the multicenter REinterventions for Type 2 Endoleak (RETE) study. J Vasc Surg. 2026. PMID: 42901252. doi:10.1016/j.jvs.2026.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。